Bernd Kasper, MD, PhD, discusses the significance of the FDA approval of nirogacestat for patients with desmoid tumors.
Bernd Kasper, MD, PhD
Advertisement
Articles by Bernd Kasper, MD, PhD
Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses the effect of nirogacestat on tumor volume and T2 hyperintensity in patients with desmoid tumors.
Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses future treatment approaches in the field of sarcoma and the potential role of imatinib (Gleevac).
Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses imatinib (Gleevac) versus sorafenib (Nexavar) as treatments for patients with sarcoma.
Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses results of a phase II study exploring the efficacy of imatinib (Gleevac) in patients with racist progressive demoed tumors.
Advertisement
Latest Updated Articles
Dr. Kasper on Imatinib in Resistant Progressive Desmoid TumorsJanuary 20th 2017
Dr. Kasper on Imatinib Versus Sorafenib in SarcomaMarch 17th 2017
Dr. Kasper on Future Treatment Approaches in SarcomaMay 17th 2017
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
3
AI Tools Show Early Promise Across Drug Discovery, Clinical Decision-Making in Lung Cancer
4
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
5